The MARK3 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte line, designed to disrupt the MARK3 gene encoding microtubule affinity-regulating kinase 3. This product provides a heterogeneous pool of cells harboring targeted gene disruptions, enabling loss-of-function studies without clonal selection artifacts. The polyclonal format offers a genetically diverse background that reflects population-level responses, making it suitable for dissecting MARK3-dependent signaling and cellular processes in a cancer-relevant context.
Raji cells were originally derived from a Burkitt lymphoma patient and are characterized by Epstein-Barr virus (EBV) positivity. As a B lymphocyte model, these cells mediate humoral immunity and are widely employed in immunology and oncology research. Their robust growth and well-characterized signaling properties make them an ideal platform for studying B cell biology, lymphomagenesis, and therapeutic target validation. The knockout variant thus extends the utility of this cell line to detailed mechanistic investigations.
MARK3 is a serine/threonine kinase that phosphorylates microtubule-associated proteins, including Tau, MAP2, and MAP4, thereby regulating microtubule stability and cell polarity. It also phosphorylates the cell cycle regulator CDC25C to promote G2/M transition. MARK3 is activated by upstream kinases LKB1/STK11 and AMPK, and functions downstream of Wnt ligands and PI3K/AKT signaling. The kinase interacts with scaffold proteins such as 14-3-3 and the Par3/Par6/aPKC polarity complex, while its activity is modulated by PP2A phosphatase. Through these interactions, MARK3 integrates nutrient-sensing and polarity cues to coordinate cytoskeletal dynamics and cell division.
In Raji B cells, MARK3 knockout is expected to impair microtubule organization and polarity, potentially disrupting cell migration and asymmetric division. Given its role in cell cycle progression, loss of MARK3 may alter proliferation and sensitize cells to checkpoints. Since Raji cells retain functional B cell receptor signaling, the knockout model can be used to examine how MARK3 intersects with Wnt and mTOR pathways in lymphomagenesis. The polyclonal population allows assessment of phenotypic heterogeneity and clonal evolution under selective pressures relevant to cancer.
This knockout cell model supports a broad range of applications, including investigation of B cell polarity and migration using transwell assays and immunofluorescence microscopy for microtubule architecture. It enables cell cycle analysis via flow cytometry with phospho-specific antibodies, along with dissection of Wnt, Hippo, and mTOR signaling through immunoblotting and co-immunoprecipitation of MARK3 partners such as 14-3-3. Researchers can employ quantitative RT-qPCR for transcriptional profiling and phospho-Tau ELISA to evaluate kinase activity. The cells are also valuable for drug target validation in leukemia and lymphoma. For ordering information or technical inquiries, please contact Ascent Research.
